(Q35173061)

6 August 2017

1 reference

title

Thalidomide therapy for renal cell carcinoma (English)

1 reference

6 August 2017

0 references

Robert J Amato

1

1 reference

6 August 2017

publication date

1 June 2003

1 reference

Critical Reviews in Oncology Hematology

6 August 2017

published in

1 reference

6 August 2017

volume

46 Suppl

1 reference

6 August 2017

page(s)

S59-65

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

6 August 2017

1 reference

7 January 2021

Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administrat

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

The treatment of advanced renal cell cancer with high-dose oral thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

Thalidomide: a novel template for anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900065-9

7 January 2021

10.1016/S1040-8428(03)00065-9

Identifiers

DOI

1 reference

6 August 2017

1 reference